Targeted Oncology
@TargetedOnc
Followers
21K
Following
5K
Media
6K
Statuses
45K
Oncology news and insights from leading researchers and cancer centers.
Greater New York Area
Joined July 2012
#FDA fast-tracks alnodesertib and irinotecan for ATM-negative metastatic #ColorectalCancer, showing promising efficacy and safety in early trials.
targetedonc.com
FDA fast-tracks alnodesertib and irinotecan for ATM-negative metastatic colorectal cancer, showing promising efficacy and safety in early trials.
0
0
1
Don’t miss your chance to join the exclusive conversation! 🎥 Lili Zhang, MD, shares how Case-Based Roundtable® and Community Case Forum™ discussions support and advance oncologists in their practices. 👉Don’t Miss Out—Sign Up for Invitations: https://t.co/snyapIjNCE
0
0
1
The #FDA approves a new diagnostic tool enhancing precision treatment for advanced #endometrial carcinoma, improving patient outcomes with targeted therapies. #EndometrialCancer #Gynecology #PrecisionMedicine
targetedonc.com
The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies.
0
0
2
🧬 Latest breakthroughs inside! Your dose of cutting-edge research, SERD updates, and AI in oncology is here. Flip through the new issue 👉 https://t.co/GaEvL9OXaQ
0
0
2
The #FDA clears the way for a pivotal phase 3 trial of lacutamab, promising new hope for patients with cutaneous T-cell #lymphoma.
targetedonc.com
The FDA clears the way for a pivotal phase 3 trial of lacutamab, promising new hope for patients with cutaneous T-cell lymphomas.
0
0
2
Navigate the evolving oncology landscape with confidence. Scout delivers high-quality, personalized insights to help you make informed decisions faster. Start searching now: https://t.co/A3MxAWIkV3
#HealthcareAI #OncologyUpdates
0
0
2
Tinostamustine receives #FDA orphan drug designation, promising new hope for #glioblastoma treatment with innovative dual-action mechanism. #BrainCancer
targetedonc.com
Tinostamustine receives FDA orphan drug designation, promising new hope for glioblastoma treatment with innovative dual-action mechanism.
0
0
1
A groundbreaking clinical trial begins for 225Ac-SSO110, targeting aggressive cancers like extensive-stage small cell #LungCancer and Merkel cell carcinoma. #SCLC #ESCLC
targetedonc.com
A groundbreaking clinical trial begins for 225Ac-SSO110, targeting aggressive cancers like extensive-stage small cell lung cancer and Merkel cell carcinoma.
0
1
1
🩺 Expert voices. Emerging strategies. Get the oncology insights that matter most with Chief Insights in Oncology. 🎥 Watch Now: https://t.co/g1d4j4O0Wz
#OncologyInsights #ClinicalInsights #AdvancingCare
0
1
3
📣FDA News: The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate AVZO-1418 for treatment of patients with EGFR-mutated, tyrosine kinase inhibitor-pretreated non–small cell lung cancer. https://t.co/ii98PoAIPH
#CancerNews
0
3
4
📣FDA News: FDA approval of generic dasatinib tablets improves market access and cost efficiency for CML and ALL treatment. 🔗: https://t.co/uYEe21rHuy
#CancerNews #Oncology #FDANews
1
0
2
💡The combination of bezuclastinib and sunitinib significantly improved median progression-free survival in GIST patients compared to sunitinib alone, reducing disease progression or death risk by 50%. 🔗:
targetedonc.com
A new treatment combination shows significant promise for patients with resistant gastrointestinal stromal tumors, improving survival rates and tolerability.
0
2
0
🌐A co-clinical trial determined that the triplet combination therapy of fulvestrant, palbociclib, and rogaratinib is effective only in patients with nonmutated tumors in advanced HR+, HER2-negative breast cancer. 🔗:
targetedonc.com
A co-clinical trial reveals a promising triplet therapy for advanced HR+ breast cancer, highlighting the importance of genetic profiling in treatment efficacy.
0
0
3
📸: HER2-positive patients exhibited the longest survival, while triple-negative breast cancer patients had the shortest survival among subtypes. 🔗: https://t.co/GCQqh7idMT
0
2
2
📣Zelenectide pevedotin showed a favorable safety profile and promising antitumor activity in advanced solid tumors, especially urothelial carcinoma, in the Duravelo-1 trial. #OncologyNews #CancerResearch 🔗:
targetedonc.com
Zelenectide pevedotin shows promising antitumor activity and manageable safety in advanced solid tumors, particularly urothelial carcinoma, in recent clinical trials.
0
0
3
#CommunityOncology is evolving fast so stay ahead at #CFS25! Learn how to integrate the latest therapies & diagnostic advances into everyday practice. NYC | This week | Here’s the preview: https://t.co/KFQXBFSOH2
0
0
3
A study reveals key risk factors for #pneumonitis in patients with metastatic #BreastCancer treated with T-DXd, highlighting the need for proactive management strategies.
targetedonc.com
A study reveals key risk factors for pneumonitis in metastatic breast cancer patients treated with T-DXd, highlighting the need for proactive management strategies.
0
0
1
New findings reveal promising antitumor responses in HER2-positive esophagogastric adenocarcinoma with a novel chemoimmunotherapy approach. #GICancers
targetedonc.com
New findings reveal promising antitumor responses in HER2-positive esophagogastric adenocarcinoma with a novel chemoimmunotherapy approach.
0
2
2
A phase 1b trial reveals the safety and potential efficacy of combining PolyPEPI1018 #vaccine with TAS-102 in treating advanced #ColorectalCancer.
targetedonc.com
A phase 1b trial reveals the safety and potential efficacy of combining PolyPEPI1018 vaccine with TAS-102 in treating advanced colorectal cancer.
0
1
3
Glofitamab and polatuzumab vedotin show promising efficacy and safety in treating relapsed/refractory large B-cell #lymphoma, with durable responses reported.
targetedonc.com
Glofitamab and polatuzumab vedotin show promising efficacy and safety in treating relapsed/refractory large B-cell lymphoma, with durable responses reported.
0
0
2